title: Penetration of moxifloxacin through crosslinked corneas.
abstract: OBJECTIVE
  To determine the ability of moxifloxacin to penetrate the rabbit eye after corneal collagen crosslinking (CXL) with riboflavin and ultraviolet-A light irradiation.
  
  
  METHODS
  Harlan Biotech Israel, Rehovot, Israel.
  
  
  METHODS
  Experimental study.
  
  
  METHODS
  One eye of 10 New Zealand white rabbits had CXL treatment. One month after treatment and 1 hour before an aqueous humor sample was obtained, 1 drop of 5 mg/mL moxifloxacin (Vigamox) was applied to both eyes of each rabbit every 15 minutes for a total of 4 drops. The aqueous humor samples were sent for high-performance liquid chromatography for antibiotic-concentration analysis. The eyes were enucleated and sent for histology analysis.
  
  
  RESULTS
  Moxifloxacin levels were obtained and analyzed for all 20 eyes. The mean level of moxifloxacin was 2.26 μg/mL ± 0.89 (SD) (range 1.09 to 4.20 μg/mL) in the treated eyes and 2.43 ± 1.17 μg/mL (range 0.89 to 4.72 μg/mL) in the untreated eyes. The difference between the groups was not statistically significant. Of the 10 eye pairs, lower moxifloxacin aqueous humor concentrations were found in 6 treated eyes and 4 untreated eyes.
  
  
  CONCLUSIONS
  Penetration of moxifloxacin into the anterior chamber of rabbits was not influenced by previous CXL treatment.
  
  
  BACKGROUND
  No author has a financial or proprietary interest in any material or method mentioned.
authors.affiliation: From the Ophthalmology Department (Litvin), Meir Medical Center, Kfar Saba, Harlan Biotech Israel (Ben Eliahu), the Ophthalmology Department (Rotenberg, Marcovich, Kleinmann), Kaplan Medical Center, the Weizmann Institute of Science (Marcovich), Rehovot, and the Ophthalmology Department (Zadok), Assaf Harofeh Medical Center, Rishon Lezion, Israel.
authors.forename: Gilad
authors.initials: G
authors.lastname: Litvin
authors.affiliation: From the Ophthalmology Department (Litvin), Meir Medical Center, Kfar Saba, Harlan Biotech Israel (Ben Eliahu), the Ophthalmology Department (Rotenberg, Marcovich, Kleinmann), Kaplan Medical Center, the Weizmann Institute of Science (Marcovich), Rehovot, and the Ophthalmology Department (Zadok), Assaf Harofeh Medical Center, Rishon Lezion, Israel.
authors.forename: Shmuel
authors.initials: S
authors.lastname: Ben Eliahu
authors.affiliation: From the Ophthalmology Department (Litvin), Meir Medical Center, Kfar Saba, Harlan Biotech Israel (Ben Eliahu), the Ophthalmology Department (Rotenberg, Marcovich, Kleinmann), Kaplan Medical Center, the Weizmann Institute of Science (Marcovich), Rehovot, and the Ophthalmology Department (Zadok), Assaf Harofeh Medical Center, Rishon Lezion, Israel.
authors.forename: Michael
authors.initials: M
authors.lastname: Rotenberg
authors.affiliation: From the Ophthalmology Department (Litvin), Meir Medical Center, Kfar Saba, Harlan Biotech Israel (Ben Eliahu), the Ophthalmology Department (Rotenberg, Marcovich, Kleinmann), Kaplan Medical Center, the Weizmann Institute of Science (Marcovich), Rehovot, and the Ophthalmology Department (Zadok), Assaf Harofeh Medical Center, Rishon Lezion, Israel.
authors.forename: Arie L
authors.initials: AL
authors.lastname: Marcovich
authors.affiliation: From the Ophthalmology Department (Litvin), Meir Medical Center, Kfar Saba, Harlan Biotech Israel (Ben Eliahu), the Ophthalmology Department (Rotenberg, Marcovich, Kleinmann), Kaplan Medical Center, the Weizmann Institute of Science (Marcovich), Rehovot, and the Ophthalmology Department (Zadok), Assaf Harofeh Medical Center, Rishon Lezion, Israel.
authors.forename: David
authors.initials: D
authors.lastname: Zadok
authors.affiliation: From the Ophthalmology Department (Litvin), Meir Medical Center, Kfar Saba, Harlan Biotech Israel (Ben Eliahu), the Ophthalmology Department (Rotenberg, Marcovich, Kleinmann), Kaplan Medical Center, the Weizmann Institute of Science (Marcovich), Rehovot, and the Ophthalmology Department (Zadok), Assaf Harofeh Medical Center, Rishon Lezion, Israel. Electronic address: guy.kleinmann@hsc.utah.edu.
authors.forename: Guy
authors.initials: G
authors.lastname: Kleinmann
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics*; D001082:Aqueous Humor / Q000378:metabolism*; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid; D003094:Collagen / Q000378:metabolism*; D003315:Cornea / Q000187:drug effects / Q000378:metabolism*; D003432:Cross-Linking Reagents / Q000494:pharmacology*; D024841:Fluoroquinolones / Q000493:pharmacokinetics*; D000077266:Moxifloxacin; D017319:Photosensitizing Agents / Q000494:pharmacology; D011817:Rabbits; D012256:Riboflavin / Q000494:pharmacology; D014018:Tissue Distribution; D014466:Ultraviolet Rays
chemical_list: D000900:Anti-Bacterial Agents; D003432:Cross-Linking Reagents; D024841:Fluoroquinolones; D017319:Photosensitizing Agents; D003094:Collagen; D012256:Riboflavin; D000077266:Moxifloxacin